Tsjekkia - tsjekkisk - SUKL (Státní ústav pro kontrolu léčiv)

ipsen pharma, boulogne-billancourt array - 13877 botulotoxin typ a - prášek pro injekční roztok - 500su - botulotoxin

Tsjekkia - tsjekkisk - SUKL (Státní ústav pro kontrolu léčiv)

ipsen pharma, boulogne-billancourt array - 13877 botulotoxin typ a - prášek pro injekční roztok - 300su - botulotoxin

USA - engelsk - NLM (National Library of Medicine)

ipsen biopharmaceuticals, inc. - botulinum toxin type a (unii: e211kpy694) (botulinum toxin type a - unii:e211kpy694) - botulinum toxin type a 500 u - dysport is indicated for the treatment of cervical dystonia in adults. dysport is indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with procerus and corrugator muscle activity in adults less than 65 years of age. dysport is indicated for the treatment of spasticity in patients 2 years of age and older. dysport is contraindicated in patients with: - known hypersensitivity to any botulinum toxin products, cow's milk protein, or to any of the components in the formulation [see warnings and precautions (5.3)]. this product may contain trace amounts of cow's milk protein [see description (11)] . - infection at the proposed injection site(s). risk summary there are no adequate and well-controlled clinical studies with dysport in pregnant women. dysport should only be used during pregnancy if the potential benefit justifies the potential risk to the fetus. dysport produced embryo-fetal toxicity in relation to maternal toxicity when given to pregnant rats and

USA - engelsk - NLM (National Library of Medicine)

galderma laboratories, l.p. - botulinum toxin type a (unii: e211kpy694) (botulinum toxin type a - unii:e211kpy694) - botulinum toxin type a 300 u - dysport is indicated for the treatment of cervical dystonia in adults. dysport is indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with procerus and corrugator muscle activity in adults less than 65 years of age. dysport is indicated for the treatment of spasticity in patients 2 years of age and older. dysport is contraindicated in patients with: - known hypersensitivity to any botulinum toxin products, cow's milk protein, or to any of the components in the formulation [see warnings and precautions (5.3)] .  this product may contain trace amounts of cow's milk protein [see description (11)] . - infection at the proposed injection site(s). risk summary there are no adequate and well-controlled clinical studies with dysport in pregnant women. dysport should only be used during pregnancy if the potential benefit justifies the potential risk to the fetus. dysport produced embryo-fetal toxicity in relation to maternal toxicity when given to pregn

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

ipsen pty ltd - clostridium botulinum type a toxin haemagglutinin complex, quantity: 500 u - injection, powder for - excipient ingredients: albumin; lactose monohydrate - dysport is indicated for symptomatic treatment of focal spasticity of: ? upper limbs in adults ? lower limbs in adults ? upper limbs in children aged 2 years and older ? lower limbs in children aged 2 years and older,dysport is indicated in adults for the treatment of: ? spasmodic torticollis ? blepharospasm ? hemifacial spasm ? moderate to severe glabellar lines and / or lateral canthal lines (crow?s feet)

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

ipsen pty ltd - clostridium botulinum type a toxin haemagglutinin complex, quantity: 125 u - injection, powder for - excipient ingredients: albumin; lactose monohydrate - dysport is indicated for symptomatic treatment of focal spasticity of: ? upper limbs in adults ? lower limbs in adults ? upper limbs in children aged 2 years and older ? lower limbs in children aged 2 years and older,dysport is indicated in adults for the treatment of: ? spasmodic torticollis ? blepharospasm ? hemifacial spasm ? moderate to severe glabellar lines and / or lateral canthal lines (crow?s feet)

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

ipsen pty ltd - clostridium botulinum type a toxin haemagglutinin complex, quantity: 300 u - injection, powder for - excipient ingredients: albumin; lactose monohydrate - dysport is indicated for symptomatic treatment of focal spasticity of: ? upper limbs in adults ? lower limbs in adults ? upper limbs in children aged 2 years and older ? lower limbs in children aged 2 years and older,dysport is indicated in adults for the treatment of: ? spasmodic torticollis ? blepharospasm ? hemifacial spasm ? moderate to severe glabellar lines and / or lateral canthal lines (crow?s feet)

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - clostridium botulinum type a toxin haemagglutinin complex 500 u - powder for injection - 500 u - active: clostridium botulinum type a toxin haemagglutinin complex 500 u excipient: albumin lactose monohydrate - dysport is also indicated for the symptomatic treatment of axillary hyperhidrosis (excessive sweating)

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - clostridium botulinum type a toxin haemagglutinin complex 300 u - powder for injection - 300 u - active: clostridium botulinum type a toxin haemagglutinin complex 300 u excipient: albumin lactose monohydrate - dysport is also indicated for the symptomatic treatment of axillary hyperhidrosis (excessive sweating)

Spania - spansk - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

ipsen pharma, s.a. - toxina botulinica tipo a - excipientes: lactosa monohidrato - agentes relajantes musculares de acciÓn perifÉrica - otros agentes relajantes musculares de acción periférica - botulínica, toxina